Modality
ASO
MOA
TYK2i
Target
APOC3
Pathway
Notch
CKD
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
May 2021
→ Dec 2027
Phase 1Current
NCT06106511
1,715 pts·CKD
2021-05→2027-12·Recruiting
1,715 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-071.7y awayPh2 Data· CKD
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2027-12-07 · 1.7y away
CKD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06106511 | Phase 1/2 | CKD | Recruiting | 1715 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 |